
Michael Adeogun, Head of Life Sciences and Health at National Physical Laboratory, discusses the importance of effective measurement for the …

Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …

Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 …

On 18 December 2017, the District of New Jersey filed a complaint against Dr. Reddy’s Laboratories for failing to comply …

Liberal Democrat MP Norman Lamb has drawn attention to what he has called an “extraordinary scandal” in which an estimated …

Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify …

AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …

Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …

AstraZeneca and X-Chem are to expand their existing drug discovery collaboration, it has emerged. The partnership marks the third agreement …

Following on from this week’s earlier piece on real world evidence, Jacqueline Corrigan-Curay, Director of CDER’s Office of Medical Policy at the FDA, …

NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …

Evidence is mounting against the efficacy of the common morning sickness pill pyridoxine-doxylamine (Diclegis, Diclectin), as new study data reveals …

For women, possessing a mutated BRCA1 or BRCA2 gene significantly increases the chances of developing breast or ovarian cancer; at …